Angela C. Hirbe

The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.

This study integrates multi-omics data from MPNSTs to identify drug targets based on chromosome 8q status, suggesting PLK1 and EGFR inhibitors could be effective in different subtypes.

The paper develops and characterizes semi-immortalized Schwann cell lines from NF1-associated cutaneous neurofibromas to aid in studying and developing therapies for NF1.

This study identifies IGF2 as a therapeutic target in PRC2-deficient MPNSTs by linking PRC2 loss to chromatin remodeling and activation of the IGF2-IGF2BP axis.

The paper provides an integrated genomic analysis of NF1-associated peripheral nerve sheath tumors using RNAseq and WES data from 73 and 114 samples, respectively, accessible via the NF Data Portal.

This study identifies YAP signaling as a driver of resistance to MEK and AKT inhibitors in NF1-related MPNSTs using preclinical models and spatial transcriptomics.

This study delivers SOD2 mRNA via nanoparticles to mice with abdominal aortic aneurysms, reducing aneurysm expansion and rupture by enhancing antioxidant activity and modulating inflammatory pathways.

This study uses plasma cfDNA fragmentomics to distinguish malignant, pre-malignant, and non-malignant NF1-associated peripheral nerve sheath tumors.

The paper uses statistical and machine learning methods to analyze NF1 tumor genomic data, identifying key signaling pathways and molecular features associated with different tumor types and potential drug targets.